Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745423 | 1.00 | HTR2C (0.41) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23216186 | 0.76 | SLC6A2 (0.44) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29745331 | 0.76 | SLC6A2 (0.44) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23216744 | 0.74 | ALDH1A1 (0.43) | HTR2CHTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL23216837 | 0.73 | MEN1 (0.37) | HTR2CHTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL23215279 | 0.73 | HTR2C (0.41) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29782207 | 0.73 | HTR2C (0.41) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23215278 | 0.73 | HTR2C (0.41) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23215274 | 0.73 | HTR2C (0.41) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17962714 | 0.73 | HTR2C (0.51) | HTR2CHTR2ASLC6A4ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | HTR2C 920/4885HTR2A 1620/4885SLC6A4 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.